Home » Stocks » IVA

Inventiva SA (IVA)

Stock Price: $13.27 USD -0.12 (-0.90%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
Market Cap 516.97M
Revenue (ttm) 5.26M
Net Income (ttm) -33.62M
Shares Out 38.63M
EPS (ttm) -0.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $13.27
Previous Close $13.39
Change ($) -0.12
Change (%) -0.90%
Day's Open 13.25
Day's Range 13.25 - 13.34
Day's Volume 4,442
52-Week Range 9.01 - 19.06

News

There are no news available yet.

About IVA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. Th... [Read more...]

Industry
Biotechnology
IPO Date
Jul 10, 2020
CEO
Frederic Cren
Employees
88
Stock Exchange
NASDAQ
Ticker Symbol
IVA
Full Company Profile

Financial Performance

In 2020, Inventiva's revenue was $5.26 million, a decrease of -53.39% compared to the previous year's $11.29 million. Losses were -$33.62 million, 11.3% more than in 2019.

Financial Statements